Voyager Therapeutics, Inc. Income Statement
VYGR|11 years of annual SEC 10-K data (FY2015-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 11 fiscal years. All figures from audited SEC 10-K filings.
Voyager Therapeutics, Inc. reported $250M in revenue and $132M in net income for FY2025. Revenue has grown at a 58.0% compound annual rate over the past 10 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $250.0M | $40.9M | $37.4M | $171.1M | $104.4M | $7.6M | $10.1M | $14.2M | $17.3M | $17.3M | $2.6M |
| SG&A Expense | $35.8M | $31.0M | $37.2M | $35.0M | $36.3M | $33.8M | $19.7M | $13.3M | $9.9M | $5.5M | $1.4M |
| R&D Expense | $92.2M | $60.8M | $73.8M | $108.8M | $119.7M | $64.9M | $62.3M | $42.2M | $27.7M | $8.9M | $2.3M |
| Operating Income | $122.0M | -$50.8M | -$73.6M | $27.4M | -$51.7M | -$91.1M | -$71.9M | -$41.3M | -$20.3M | -$14.4M | -$3.8M |
| Income Tax | $1.4M | $16.0K | $16.0K | $16.0K | - | -$180.0K | -$180.0K | $52.0K | $52.0K | $0 | - |
| Net Income | $132.3M | -$46.4M | -$71.2M | $36.7M | -$43.6M | -$88.3M | -$70.7M | -$40.2M | -$29.7M | -$16.3M | -$3.8M |
| EPS (Basic) | $3.08 | -$1.21 | -$1.89 | $0.99 | -$1.21 | -$2.75 | - | - | - | - | - |
| EPS (Diluted) | $2.97 | -$1.21 | -$1.89 | $0.98 | -$1.21 | -$2.75 | -$2.64 | -$1.59 | $9.14 | $27.83 | $1629.68 |
| Shares Outstanding | 54.7M | 44.0M | 38.6M | 37.9M | 37.4M | 36.9M | 32.4M | 31.6M | 25.6M | 24.9M | 814.8K |
| Operating Margin | 48.8% | -124.3% | -196.8% | 16.0% | -49.5% | -1195.6% | -709.1% | -290.4% | -116.9% | -82.9% | -146.2% |
| Profit Margin | 52.9% | -113.5% | -190.3% | 21.5% | -41.8% | -1158.8% | -697.6% | -282.6% | -171.2% | -94.1% | -148.8% |